Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINBO MMRD-GREEN: Durvalumab as adjuvant therapy in mismatch repair-deficient high-risk endometrial cancer
2021-000518-40Phase 3Active
- Sponsor
- Leiden University Medical Center
- Start
- Aug 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of durvalumab in endometrial cancer (EC) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: 3-year recurrence-free survival. Started Aug 2021; status: active.
02
Drugs
durvalumab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2021-000518-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000518-40.